Oncogenes, rather than DNA damage, may provide the key signal to p53 to trigger tumour suppression.
Abstract
The tumour-suppressor protein p53 provides the most important genetic defence against cancer1 and is activated in response to DNA damage and to oncogenic signalling, both of which occur almost universally in malignant tumours. But the relative contribution of these two pathways in inducing p53-dependent protection against cancer is unclear. Here we show that p53-dependent protection against cancer is lost in mice that have been genetically manipulated so that their p53 is activated in response to DNA damage but not to oncogenic signalling. We conclude that oncogenic signalling is the critical event that elicits p53-dependent protection and that the DNA-damage stimulus is less important.
Similar content being viewed by others
Main
DNA damage and oncogenic signalling are communicated to p53 through separate routes, which are, respectively, a p53-phosphorylation cascade that involves the ATM/Chk2/ATR/Chk1 series of kinases, and a p53-stabilization pathway that requires the tumour-suppressor protein ARF and the ubiquitin-ligase MDM2 (ref. 1).
To investigate the role of oncogenic signalling in p53-mediated protection against cancer, we used mice with two genetically engineered traits: one had no ARF allele (ARFnull mice)2 and the other had a 'super' p53 allele3 (p53super mice; these mice carry a single additional transgenic copy of the intact p53 gene, which behaves in the same way as endogenous p53). Compared with wild-type mice (p53wt mice), which have just two copies of p53, the p53super mice have additional protection against cancer development3. This experimental system is therefore well suited for quantifying p53-dependent protection against cancer.(See supplementary information for methods.)
Before analysing their susceptibility to cancer, we confirmed that ARFnull mice respond normally to DNA damage4,5 by showing that apoptosis of their thymocytes after irradiation was unaffected (Fig. 1a). We found that mice with the p53super allele showed the same enhancement of apoptosis irrespective of whether ARF was present or absent (Fig. 1a). However, ARFnull cells were unable to respond effectively to oncogenic signalling6,7,8 and underwent neoplastic transformation by oncogenes in vitro, irrespective of the presence or absence of the p53super allele (Fig. 1b).
As p53 responds normally to DNA damage in the absence of ARF, we reasoned that p53super might provide some protection against tumour development in vivo, even without the ability to detect oncogenic signalling. However, we found that p53super/ARFnull mice succumbed to spontaneous tumours at the same rate as p53wt/ARFnull mice (Fig. 1c), producing the same profile of sarcomas, lymphomas and histiocytic sarcomas (results not shown).
We also treated p53super/ARFnull and p53wt/ARFnull mice with the DNA-damaging agent 3-methyl cholanthrene. This agent produces DNA adducts and results in fibrosarcomas carrying oncogenic mutations in ras genes. This carcinogenic protocol is highly sensitive to the functionality of p53, as indicated by the greater resistance to the agent of p53super mice compared with p53wt mice3. As with the spontaneous tumours, the extra gene dose of p53 became irrelevant in the absence of ARF (Fig. 1d).
Together, our results indicate that the cancer-protective activity of p53 is abolished in the absence of ARF. We conclude that oncogenic signalling is critical for triggering protection by p53, whereas activation of p53 as a result of DNA damage has a lesser impact on the ultimate development of tumours. Although there are differences in these pathways in mice and humans, our findings may also explain the high incidence of ARF loss in human cancers9, as well as the low incidence of mutations in the kinase enzymes of the p53-phosphorylation cascade10 that is induced by DNA damage.
References
Harris, S. L. & Levine, A. J. Oncogene 24, 2899–2908 (2005).
Kamijo, T. et al. Cell 91, 649–659 (1997).
Garcia-Cao, I. et al. EMBO J. 21, 6225–6235 (2002).
Stott, F. J. et al. EMBO J. 17, 5001–5014 (1998).
Kamijo, T. et al. Cancer Res. 59, 2464–2469 (1999).
Palmero, I., Pantoja, C. & Serrano, M. Nature 395, 125–126 (1998).
Zindy, F. et al. Genes Dev. 12, 2424–2433 (1998).
de Stanchina, E. et al. Genes Dev. 12, 2434–2442 (1998).
Sharpless, N. E. Mutat. Res. 576, 22–38 (2005).
Bartek, J. & Lukas, J. Cancer Cell 3, 421–429 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
Suuplementary methods and table. (DOC 86 kb)
Rights and permissions
About this article
Cite this article
Efeyan, A., Garcia-Cao, I., Herranz, D. et al. Policing of oncogene activity by p53. Nature 443, 159 (2006). https://doi.org/10.1038/443159a
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/443159a
This article is cited by
-
Deconstructing networks of p53-mediated tumor suppression in vivo
Cell Death & Differentiation (2018)
-
MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation
Oncogene (2017)
-
p19Arf is required for the cellular response to chronic DNA damage
Oncogene (2016)
-
Antitumor mechanisms when pRb and p53 are genetically inactivated
Oncogene (2015)
-
Unravelling mechanisms of p53-mediated tumour suppression
Nature Reviews Cancer (2014)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.